Overactive Bladder/Enuresis Archives - Page 19 of 20 - Renal and Urology News

Overactive Bladder/Enuresis

Experimental Agent Ameliorates OAB

MILAN—New data demonstrate that the investigational agent fesoterodine, at both the 4 or 8 mg per day dose, is associated with significant improvements in overactive bladder (OAB) symptoms.

Solifenacin Works for Difficult OAB

Patients with severely bothersome overactive bladder (OAB) symptoms who have failed treatment with tolterodine ER may benefit by switching to solifenacin, research suggests.

Once-Daily Formulation for OAB Treatment Approved

Sanctura XR (trospium chloride extended-release capsules), made by Indevus Pharmaceuticals, Inc., of Lexington, Mass., has been approved for the once-daily treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Next post in News